DSP107, a Novel CD47x4-1BB targeting agent

Time: 1:30 pm
day: Day One Track B PM


Virtual Presentation

  • Improving Target Specificity and Activity Through the Use of Bispecific Fusion Protein
  • Designing bispecific agent to successfully mediate dual activation of innate and adaptive immune systems
  • Transforming safety profile and avoiding hematological toxicities
  • Enhancing the potential for the treatment of solid and hematological malignancies